Treatment with the PCSK9 inhibitor alirocumab has been proven successful in reducing both cardiovascular events and all-cause mortality in heart patients, according to ODYSSEY results presented at ACC 18 in Orlando, but the debate surrounding the cholesterol-busting drug is far from over.

The hemophilia drug market in the United States is saturated with 28 medications—and another 21 currently in development—to treat about 20,000 patients. But the money is right for drug companies, Kaiser Health News reports in a March 8 story.

Accelerating the integration of digital healthcare tools in a responsible, clinically meaningful way is the primary focus of the American College of Cardiology’s innovation agenda, said John Rumsfeld, MD, PhD, the college’s chief innovation officer.

Several state and federal officials have committed to addressing concerns about “gag clauses” which prevent pharmacists from telling patients about cheaper alternatives to obtain prescription medications without health insurance.

Program planners predict shared decision making (SDM) will be a hot topic when the American College of Cardiology (ACC) hosts its 2018 Scientific Session March 10-12 in Orlando. They’ve planned a two-part intensive, as well as several other sessions, around the subject.

Known for its conservative and what many call risk-averse nature, the Food and Drug Administration (FDA) seems to be headed in a bold and ambitious direction under Commissioner Scott Gottlieb, MD. What will his leadership mean for cardiology?

To tackle health disparities between Chicago’s West Side and wealthier, predominantly white neighborhoods elsewhere in the city, Rush University Medical Center is leading a group of nine hospitals and health systems to make investments and hire people from disadvantaged communities.

DUBLIN — February 20, 2018 — Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2018, which ended January 26, 2018.